Skip to main content
OpenTrials

Clinical trial condition

Imprinting Disorders

Explore clinical trials studying Imprinting Disorders. Study availability and eligibility vary by location and protocol.

143 public trials 25 recruiting studies
Refine in advanced search Browse all conditions

Imprinting Disorders trial results

Completed

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

NCT05011851

Conditions
Abnormalities, Multiple, Angelman Syndrome, Central Nervous System Diseases, +7 more
Locations
  • Sydney Children's Hospital Randwick, New South Wales, Australia
  • Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service South Brisbane, Queensland, Australia
  • Austin Health Heidelberg, Victoria, Australia
View Trial Details
Completed

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

NCT05322096

Conditions
Abnormalities, Multiple, Body Weight, Chromosome Disorders, +16 more
Locations
  • Rady Children's Hospital-San Diego San Diego, California, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • Maimonides Medical Center Brooklyn, New York, United States
  • NYU Langone Hospital-Long Island Mineola, New York, United States
View all 23 locations
View Trial Details
Completed

Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

NCT01906866

Conditions
Abnormalities, Multiple, Angelman Syndrome, Autism Spectrum Disorder, +30 more
Locations
  • Southwest Autism Research and Resource Center (SARRC) Phoenix, Arizona, United States
  • Crystal BioMedical Research, LLC Miami Lakes, Florida, United States
  • Lake Mary Pediatrics Orange City, Florida, United States
  • Mate Lazlo West Palm Beach, Florida, United States
View all 28 locations
View Trial Details
Completed

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

NCT03714373

Conditions
Abnormalities, Multiple, Chromosome Disorders, Congenital Abnormalities, +13 more
Locations
  • University of California, Irvine Orange, California, United States
  • Stanford University Palo Alto, California, United States
  • Rady Children's Hospital San Diego San Diego, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
View all 28 locations
View Trial Details

Related conditions